We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Emv Capital Plc | LSE:EMVC | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 53.00 | 3,506 | 07:31:16 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 52.00 | 54.00 | 53.00 | 53.00 | 53.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.45M | -2.64M | -0.1121 | -4.73 | 12.49M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:40:31 | O | 55,000 | 52.30 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 08/10/2024 | 07:00 | UK RNS | EMV Capital PLC Director/PDMR Shareholding |
| 03/10/2024 | 07:00 | UK RNS | EMV Capital PLC Director/PDMR Shareholding |
| 02/10/2024 | 16:38 | UK RNS | EMV Capital PLC PDS: 36-Month Overall Survival Rate announcement |
| 30/9/2024 | 07:00 | UK RNS | EMV Capital PLC Interim Results |
| 26/9/2024 | 07:00 | UK RNS | EMV Capital PLC Name change and AIM Rule 26 website |
Emv Capital (EMVC) Share Charts1 Year Emv Capital Chart |
|
1 Month Emv Capital Chart |
Intraday Emv Capital Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 13/10/2024 09:20 by Emv Capital Daily Update Emv Capital Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EMVC. The last closing price for Emv Capital was 53p.Emv Capital currently has 23,574,000 shares in issue. The market capitalisation of Emv Capital is £12,494,220. Emv Capital has a price to earnings ratio (PE ratio) of -4.73. This morning EMVC shares opened at 53p |
Posted at 08/10/2024 22:19 by retirementfund WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING!Several Posters are posting negative spin on here trying to drive down the share price EMV Capital have stated on several occasions that they do not need to raise money. The article below represents an accurate appraisal of the company. Note further director buying announced 8.10,2024 This is my opinion |
Posted at 07/10/2024 12:19 by 1gw If you look at Companies House filings, Q-Bot registered a charge against its assets on 1st October in connection with a facility agreement (which I would interpret as Q-Bot borrowing money against the security of assets subject to the charge). The security explicitly excludes the EMVC shares that EMVC issued to Q-Bot as part of the July fundraising.I presume that is because Q-Bot has other plans for these shares. "Security Asset means any asset of the Chargor which is, or is expressed to be, subject to any Security created by this Deed but which, for the avoidance of doubt, shall at all times exclude the EMV Capital Shares." |
Posted at 05/10/2024 14:56 by retirementfund WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING WARNING!Several Posters are posting negative spin on here trying to drive down the share price EMV Capital have stated on several occasions that they do not need to raise money. The article below represents an accurate appraisal of the company. This is my opinion |
Posted at 05/10/2024 11:58 by loafofbread And there is the crack.You both admit to wanting to buy in , but at a cheaper price. Just a shame you go about it in such an underhand way. The account element is explained in the recent IM and is just the way it is done, as you both well know. "For the period to June 2025, the Group requires (including subsidiaries) a minimum of approximately £3.6 million to continue as a going concern. NetScientific and EMV Capital require £1.6m, while the other subsidiary portfolio companies Glycotest, ProAxsis and Cetromed require £2.0 million. The company is well on it's way to achieving the £1.6M in annual revenues and Glycotest/Proaxis/Ce As mentioned before they have so many assets that could return multiple millions over the 6/12/18 months arguing over a few pence on the share price seems a bit pointless. If you are really that interested, perhaps give Ed Hooper a call or email. |
Posted at 05/10/2024 11:27 by 1gw They also do appear to have had to resort to "internal" financing of the recent Q-Bot fundraising where they contributed a material amount of the £1.5m raised by issuing new shares (albeit at a premium) and converting fees due into Q-Bot shares.The issuing of new shares to Q-Bot is interesting, given presumably Q-Bot needs cash rather than shares. There appears to be a weak "orderly market" provision in that Q-Bot has to sell the shares through the EMVC broker, but we might guess that those shares are going to create a bit of an overhang. "The Group has participated directly in the Fundraising, including: · a £349,968.22 subscription for Q-Bot shares, such amount to settled by the Company issuing to Q-Bot 411,727 new ordinary shares in the capital of the Company (Consideration Shares) at a price of £0.85 per New Share, a 35.0 per cent. premium to the closing price of the Company's ordinary shares on 29 July 2024; and · a £198,143.92 advance subscription pursuant to an ASA, converting outstanding fees due to EMV Capital into Q-Bot shares. EMV Capital's EMVC Evergreen EIS Fund has also participated in the ASA. The Consideration Shares are subject to orderly market provisions such that if they are to be disposed of they must be sold through the Company's broker." |
Posted at 05/10/2024 11:13 by 1gw I think the balance sheet and going concern statements are a matter of legitimate concern, and are one of the key things that has held me back so far from investing here.While there appear to be plenty of options to raise cash, the fact is that the near term funding requirements have increased between end-2022 and end-2023 and they have not so far managed to achieve a portfolio exit that would provide them with a decent cash buffer. Compare these sections of the going concern statement from 2022 and 2023 full year results. Note that the amount required in the near-term (broadly 1 year beyond publication of the full year results in May/June) has gone up from £1.5m to £3.6m, although it looks like the 2022 number excludes the subsidiary companies whereas for 2023 they've brought subsidiary financing into scope. Note also that in the 2023 statement they have dropped the comment about having "no current intention to pursue [a placement] in light of the Company's current share price relative to its net assets." 2022: "For the period to June 2024, the Group requires a minimum of approximately £1.5 million to continue as a going concern, assuming that its subsidiary portfolio companies continue to be fully funded by external financing as expected. This amount can be financed through several options, either on their own or in combination, including accelerating revenues at Group level, partial or full exits from portfolio company stakes, soft and non-dilutive finance, and/or a placement of NetScientific shares. Whilst a placement of NetScientific shares remains an available option, the Board has no current intention to pursue that in light of the Company's current share price relative to its net assets." 2023: "For the period to June 2025, the Group requires (including subsidiaries) a minimum of approximately £3.6 million to continue as a going concern. NetScientific and EMV Capital require £1.6m, while the other subsidiary portfolio companies Glycotest, ProAxsis and Cetromed require £2.0 million. This amount can be financed through several options, either on their own or in combination. The subsidiary companies plan to be funded by external financing, as they have done in 2023. This could include convertible loans, equity or debt finance. The Board's plans for satisfying the going concern needs of NetScientific and EMV Capital are primarily based on service fees for corporate finance, value creation services, fund management and other fees. The Board plans to sell various portfolio assets in part or in full in order to meet the funding requirements. The Board can also consider the option of a placement of NetScientific shares." |
Posted at 02/10/2024 07:46 by sev22 A venture capital company on a huge discount.Shares trade on a near-70 per cent discount and you're getting its carried interests thrown in for free. Published on October 1, 2024 by Simon Thompson *Assets under management up 44 per cent to £106.7mn *£41mn director fair valuation of direct holdings *Managed and third-party holdings up 71 per cent to £65.7mn Aim-traded investment and fund management company EMV Capital (EMVC:51.5p), formerly Netscientific, has expanded its portfolio to more than 70 companies and increased total AUM above £100mn for the first time in its history. In May 2024, the deeptech and life sciences venture capital group was appointed as investment manager to Cambridge-based Martlet Capital, an early-stage venture capital fund that has a £24.1mn portfolio of unquoted investments. EMV is managing the funds on a discretionary basis and will earn annual recurring investment management fees of more than £0.5mn for a minimum of four years as well as earning carried interest fees based on the increase in fair value of each portfolio company. The addition of Martlet accounted for three-quarters of the £32.7mn rise in the group’s AUM in the first half, the other contributing factor being an increase in the directors’ fair valuation of EMV’s directly held unquoted investment portfolio from £31.1mn to £38.5mn. It was driven mainly by gains on two investee companies: DeepTech Recycling, a plastic recycling technology business offering an innovative solution to the environmental challenges of plastic pollution; and ProAxsis, a respiratory diagnostics company and a spin-out from Queens University Belfast. The carrying valuation of investee company DeepTech accounted for £1.8mn of the portfolio increase after EMV led a £2.1mn syndicated fundraising that increased the value of the company’s 21.2 per cent equity stake to £1.8mn. The gain was even larger on EMV’s holding in ProAxsis after the company closed a £1.8mn investment round led by EMV at a read-through valuation that more than doubled the value of the group’s 88 per cent stake to £8mn. Deep discount to fair valuation. It’s only fair to point out that investors continue to take a cautious approach to the directors’ fair valuations, that small-cap investment companies are out of favour and that EMV reported a first-half pre-tax loss of £0.6mn on its core activities. However, the undervaluation of EMV is extreme as its market capitalisation of £12.5mn (51.5p) is almost 70 per cent less than the £41mn (171p) director valuation of the directly held portfolio. That seems incredibly harsh given that several investee companies have been raising capital at read-through valuations that fully support the directors’ valuations. Moreover, EMV has significant carried interests on third-party fund holdings, albeit these are difficult to value and will take time to realise. EMV also holds a 3 per cent stake currently worth £3.1mn (£2.5mn in interim accounts) in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), a clinical-stage company that is developing cancer immunotherapies and infectious disease vaccines, which could be readily realised. So, having suggested buying the shares at 64p in my 2023 Bargain Share Portfolio, I can see potential for divestments and exits from several investee companies to narrow EMV’s share price discount in more benign market conditions for microcap companies. RECOVERY BUY. |
Posted at 01/10/2024 09:31 by loafofbread At this point in time the share price is 50p and the assets are worth £2.00.Looking forward on any time line this is as dysfunctional as I've ever seen on Aim. Almost all our assets are performing well and are either at sales or on the cusp of sales. Perhaps sell the lot within 3 years and return the £2.50+ to shareholders and just go forward with the EMV asset manager? |
Posted at 27/9/2024 06:27 by btgman No one will argue that it's frustrating. If you have time and patience it's an incredible opportunity. They don't need to raise money. They have incredible assets with huge upside that you can currently buy at an insane discount to current NAV let alone future NAV. They will get exits in due course and shareholders will get multiples of current share price.AIMHO GLA BTG |
Posted at 26/9/2024 08:05 by weatherman NetScientific plc("NetScientific" or the "Company") Name change and AIM Rule 26 website NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, is pleased to announce that it has changed its name to "EMV Capital plc". Regulatory information concerning the Company's name change The Company was issued by Companies House with a change of name certificate on 25 September 2024 and the name change from "NetScientific plc" to "EMV Capital plc" became effective immediately upon such receipt. Similarly, the Company's wholly owned venture capital and corporate finance firm, EMV Capital Limited, has changed its name to EMV Capital Partners Limited with immediate effect. The Company confirms that its change of name has been notified to the London Stock Exchange and trading in the Company's shares under the new company name and new TIDM code, "EMVC", is expected to commence at 8.00 a.m. on 26 September 2024. The Company's ISIN and SEDOL remain unchanged. In conjunction with its name change, the Company's website address will change to emvcapital.com. All information required by Rule 26 of the AIM Rules for Companies will be located on the "Investors" section of the website with effect from 8.00 a.m. on 26 September 2024. Shareholders rights are unaffected by these changes and existing share certificates should be retained and remain valid. Background to the Company's name change and rebranding The rebranding marks the culmination of NetScientific's strategic evolution, since acquiring EMV Capital in 2020, to a fully integrated venture capital and corporate finance business. The Group has grown substantially in both scale and scope since its inception. In 2019, the Group's portfolio fair value stood at approximately £8 million. Today, through its capital-efficient model and strategic value-creation services, the Group has established itself as a key player in venture capital, spanning deep tech, life sciences, and other innovative sectors. The EMV Capital brand, used by the Group since 2020, is already highly regarded and well established in this space, and as such the name change and rebranding across the Group is a logical step towards unifying the Group's offerings to its stakeholders. EMV Capital plc now manages a diversified portfolio of over 70 companies with estimated AUM exceeding £100 million (as announced on 13 June 2024), significantly expanding beyond its origins and is uniquely positioned to leverage its expertise across fund management, corporate finance, and portfolio growth services to deliver positive returns for investors, even when market conditions remain challenging. As EMV Capital plc, the Group continues its expansion beyond life sciences into deep tech, including sectors such as sustainability, digital health, and advanced materials. The Company's ability to provide fund management, corporate finance, and syndication services across its portfolio enables it to identify, nurture, and accelerate the growth of early-stage companies. By offering hands-on support through each growth phase, EMV Capital is committed to helping companies scale while delivering meaningful societal impact. With a goal to further grow Assets Under Management, the Group aims to scale its capital-efficient investment model, expand its fund management practice, and enhance the value of its portfolio through targeted investments and value-creation services. Dr. Ilian Iliev, CEO of EMV Capital plc, commented: "Since acquiring EMV Capital in 2020, we have consolidated our operations, significantly grown our portfolio, and expanded our strategic focus. This new identity for our Group reflects our business today-an agile, multi-sector venture capital firm committed to delivering superior returns from innovative, high-growth companies. "With Assets Under Management having surpassed £100 million, this milestone highlights our success in navigating a challenging market and underscores our ambitious plans for the future. Our continued focus on deep tech and life sciences, combined with our value-creation approach, positions EMV Capital to be at the forefront of driving the next wave of innovation and shareholder value." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
